Clinical trial
Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)
NCT00382460 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00382460 |
|---|---|
| Title | Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22) |
| Official title | Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22) |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Actue Coronary Syndromes |
| Intervention type | Drug |
| Interventions | PRAVASTATIN SODIUM |
| Enrollment | 4,000 |
| Start date | Nov 1, 2000 |
| Primary completion | Dec 1, 2003 |
| Completion | Dec 1, 2003 |
| First posted | Sep 29, 2006 |
| Last update posted | Apr 15, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: